Syndax Pharmaceuticals (NASDAQ:SNDX) Cut to Sell at StockNews.com

StockNews.com cut shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a hold rating to a sell rating in a report issued on Saturday.

SNDX has been the subject of several other research reports. Citigroup boosted their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. Stifel Nicolaus increased their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. The Goldman Sachs Group boosted their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Bank of America increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, UBS Group started coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $37.64.

Syndax Pharmaceuticals Trading Up 4.0 %

Shares of NASDAQ:SNDX opened at $16.73 on Friday. The stock has a market capitalization of $1.43 billion, a PE ratio of -4.77 and a beta of 0.92. Syndax Pharmaceuticals has a 1 year low of $15.00 and a 1 year high of $25.34. The firm has a fifty day moving average price of $18.60 and a 200 day moving average price of $19.97.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same period in the prior year, the company posted ($0.73) EPS. On average, sell-side analysts forecast that Syndax Pharmaceuticals will post -3.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares during the period. Sei Investments Co. increased its position in Syndax Pharmaceuticals by 2.5% in the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after purchasing an additional 991 shares during the period. California State Teachers Retirement System raised its holdings in Syndax Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock worth $1,822,000 after purchasing an additional 1,150 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in Syndax Pharmaceuticals during the 2nd quarter valued at about $27,000. Finally, Values First Advisors Inc. bought a new position in shares of Syndax Pharmaceuticals in the 3rd quarter valued at about $30,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).